SGLT2 inhibitors have recently been demonstrated to markedly reduce cardiovascular mortality with highly significant reduction in admissions for heart failure and end-stage renal disease, despite modest effects on long-term glycemic control [ 1 , 2 , 6 ].
← all excerpts
Empagliflozin influences blood viscosity and wall shear stress in subjects with type 2 diabetes mellitus compared with incretin-based therapy.
1
—
—